Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Linde
LIN
|
+$554M |
| 2 |
Apple
AAPL
|
+$513M |
| 3 |
Illumina
ILMN
|
+$360M |
| 4 |
argenx
ARGX
|
+$304M |
| 5 |
CTLT
CATALENT, INC.
CTLT
|
+$235M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$482M |
| 2 |
Sherwin-Williams
SHW
|
+$314M |
| 3 |
AbbVie
ABBV
|
+$310M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$244M |
| 5 |
Atlassian
TEAM
|
+$233M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.85% |
| 2 | Healthcare | 19.69% |
| 3 | Industrials | 10.47% |
| 4 | Financials | 10.02% |
| 5 | Consumer Discretionary | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Driven Brands
DRVN
$2.07B
| $64.5M | 0.04% |
2,129,029
+49,479
| +2% | +$1.4M |
|
|
AGTI
327
DELISTED
Agiliti Inc
AGTI
| $64.2M | 0.04% |
4,017,437
-1,365,203
| -25% | -$23.5M |
|
328
Seres Therapeutics
MCRB
$50.2M
| $64.1M | 0.04% |
565,041
+2,626
| +0.5% | +$284K |
|
329
Under Armour Class C
UA
$2.42B
| $63.3M | 0.04% |
7,419,022
+2,612,130
| +54% | +$24M |
|
|
IMGN
330
DELISTED
Immunogen Inc
IMGN
| $63.2M | 0.04% |
16,450,081
+13,302,505
| +423% | +$56.7M |
|
|
AVDL
331
DELISTED
Avadel Pharmaceuticals
AVDL
| $62.5M | 0.04% |
6,826,787
+5,619,257
| +465% | +$46.2M |
|
|
CCC
332
CCC Intelligent Solutions
CCC
$4.11B
| $62.4M | 0.04% |
6,958,175
+601,543
| +9% | +$5.35M |
|
333
Zai Lab
ZLAB
$2.65B
| $62.2M | 0.04% |
1,871,042
+276,417
| +17% | +$10.6M |
|
334
Brown-Forman Class B
BF.B
$12.9B
| $61.9M | 0.04% |
962,445
+322,597
| +50% | +$21M |
|
335
Cardinal Health
CAH
$55.5B
| $61.1M | 0.04% |
809,323
+205,321
| +34% | +$15.5M |
|
336
Thor Industries
THO
$4.14B
| $61M | 0.04% |
766,013
-103,797
| -12% | -$9.16M |
|
337
Entegris
ENTG
$22B
| $60.8M | 0.04% |
741,794
-60,062
| -7% | -$4.87M |
|
338
S&P Global
SPGI
$121B
| $60.7M | 0.04% |
176,276
+271
| +0.2% | +$95.4K |
|
339
Fox Class B
FOX
$23.6B
| $60.7M | 0.04% |
1,939,162
+888,625
| +85% | +$27.8M |
|
340
UBS Group
UBS
$177B
| $60.3M | 0.04% |
2,851,140
+791,312
| +38% | +$16.5M |
|
341
Alnylam Pharmaceuticals
ALNY
$29B
| $59.9M | 0.04% |
298,843
-166,545
| -36% | -$35M |
|
342
MACOM Technology Solutions
MTSI
$22.7B
| $59.7M | 0.04% |
843,376
+833,648
| +8,570% | +$56.3M |
|
343
iRhythm Holdings
IRTC
$4.1B
| $59.3M | 0.04% |
478,419
+8,603
| +2% | +$933K |
|
344
First Interstate BancSystem
FIBK
$3.56B
| $59.1M | 0.04% |
1,978,718
+106,637
| +6% | +$3.75M |
|
345
Equity Lifestyle Properties
ELS
$12.5B
| $58.9M | 0.04% |
877,571
-2,461
| -0.3% | -$167K |
|
346
Labcorp
LH
$26.1B
| $58.8M | 0.04% |
298,235
-51,922
| -15% | -$10.7M |
|
347
Innospec
IOSP
$2.29B
| $57.9M | 0.04% |
564,177
+125,785
| +29% | +$13.5M |
|
348
Descartes Systems
DSGX
$6.86B
| $57.7M | 0.04% |
716,296
-44,506
| -6% | -$3.32M |
|
|
SWAV
349
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $57.7M | 0.04% |
266,214
+259,754
| +4,021% | +$50.6M |
|
350
State Street
STT
$51.3B
| $57.7M | 0.04% |
762,362
-53,860
| -7% | -$4.54M |
|
Similar funds
Janus Henderson Group's Q1 2023 Portfolio in Review
As of Q1 2023, Janus Henderson Group held 2,845 positions worth $152B, up 8.3% from $140B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Janus Henderson Group's Q1 2023 filing shows 389 new, 1,670 increased, 578 reduced and 160 closed positions. Its largest new stake was GE HealthCare: 882,749 shares worth $72.4M. The largest sale was Meta Platforms (Facebook), an estimated $482M.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 28% a quarter earlier, followed by Healthcare and Industrials.
- Janus Henderson Group's largest Q1 2023 buy was GE HealthCare: 882,749 shares worth $72.4M.
- Janus Henderson Group added most to Linde in Q1 2023, an estimated $554M increase.
- Janus Henderson Group's biggest Q1 2023 reduction was Meta Platforms (Facebook), cutting an estimated $482M.
- Janus Henderson Group fully exited Myovant Sciences Ltd. in Q1 2023, selling an estimated $31.7M.
- Janus Henderson Group's ten largest holdings make up 24% of its $152B portfolio in Q1 2023.
- Janus Henderson Group opened 389 new positions and closed 160 in Q1 2023.
- Janus Henderson Group's portfolio value rose 8.3% quarter-over-quarter to $152B.
Based on Janus Henderson Group's 13F filing for Q1 2023, filed 15 May 2023.